Coronavirus / COVID

In a modeling study, an estimated 1.7 billion people are at an increased risk of the virus, but a much smaller percentage would require hospitalization.

A look at 3 major headlines in COVID-19 news on June 15, 2020.

In a controlled environment, investigators found sunlight affected the decay rate of the virus.

The anti-malaria drugs—and clinical trials assessing their benefit—have been under close scrutiny since the EUA was first granted in late March.

During the spring COVID-19 outbreak, an examination of Swiss people in Geneva shows only a small amount of the population with IgG antibodies.

Findings show states who followed stay-at-home orders indeed flattened their curves. Now what?

Analysis projects significant toll from virus, even with some measures in place.

In a very small international study using the antiviral, 68% of hospitalized patients on ventilators or oxygen showed improvement.

Trending infectious disease news.

A Harvard Medical School study team sought to identify individuals at elevated risk for severe COVID-19 and, among them, those at high risk of financial ruin as a result of costs associated with their care.

As the lockdown ends, the NIAID director talks the continued need for social distancing, vaccines, and emerging therapies.

This virus has multiple facets and highlights a need for real-time learning.

Infectious disease experts have recommended that stockpiles of several promising vaccine candidates be created as they enter late stage development.

A brief on today's top ID stories.

A summary of the latest infectious disease news.

COVIDSeq is a qualitative test for the detection of SARS-CoV-2 RNA.

ChromaCode now intends to use its own multiplexing technology to help launch a COVID-19 assay later this year. The assay would combine multiple respiratory viruses into a single test in anticipation of the upcoming flu season.

Patrick Soon-Shiong, MD, describes goals and expectations for the accelerated coronavirus vaccine program Operation Warp Speed.

Early administration of such therapies in this patient group not shown to help mortality rates.

A brief update on today's infectious disease news.

The test uses whole blood, plasma, or serum. The testing kit is intended to produce reliable results within 10 minutes.

Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

An assessment of 21 pediatric cases leads France investigators to believe development is due to post-viral immunological reactions.

Mild symptoms may still present high risk for SARS-CoV-2 transmission.

A quick brief on today's top infectious disease news.